1. The company’s general administrative expenses rose from $1.3 million in the second quarter of 2013 to $1.8 million. Research and development costs increased from $1.2 million in the second quarter of 2013 to $2.8 million.
2. The company formed an irritable bowel syndrome clinical advisory board in the spring of this year. Synthetics Biologics has filed new patent applications for the C-IBS program.
3. The company has also announced plans to file INDs and initiate clinical trials this year for its C. difficile and C-IBS programs.
More articles on gastroenterology:
3 Southern GI practices partner with LifeLinc Anesthesia
FDA approves colonoscopy alternative Cologuard: 4 things to know
Best ideas for entrepreneurial gastroenterologists: Public presence, ASC ownership & more
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
